United States · Health Care · USD · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average (own scale)
| Key metrics |
|---|
Amounts in USD; stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Alzamend Neuro, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Actual |
|---|
| Forecast |
|---|
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|
| ROE | -373.18% | 213.57% | 68.09% | 40.51% | 28.85% | 22.4% |
|---|---|---|---|---|---|---|
| Sector average | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% | -56.18% |
| Total Assets | $2,079,363.00 | $1,368,674.00 | $1,368,674.00 | $1,368,674.00 | $1,368,674.00 | $1,368,674.00 |
| Net Income | -$8,772,382.00 | -$23,083,815.79 | -$23,072,490.37 | -$23,076,183.23 | -$23,091,752.20 | -$23,099,673.95 |